Publications by authors named "Paul Smock"
Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24-88%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no candidate has yet reached regulatory approval. Here, we evaluate a replication-defective chimpanzee adenovirus type 3 (ChAd3)-vectored MARV Angola glycoprotein (GP)-expressing vaccine against lethal MARV challenge in macaques.
View Article and Find Full Text PDFArticle Synopsis
- The Marburg virus outbreak in Guinea and Ghana led to the formation of the MARVAC consortium, which includes experts focused on developing a vaccine.
- They aim to create a rapid response to combat the threat posed by this infectious disease.
- The discussion highlights the ongoing progress, the challenges faced in vaccine development, and potential future strategies for MARV vaccines.